Table 3: Effects on lipid profile (X ± SD) in study patients.

Treatment

Baseline

12 weeks

Changes (%)

 

 Low-density lipoprotein cholesterol (LDL-C) (mmol/L)

Policosanol

3.02 ± 0.76

2.55 ± 0.72*+++

-15.6+++

Placebo

3.05 ± 0.81

3.26 ± 0.82

+0.8

 

 Total cholesterol (mmol/L) 

Policosanol

4.40 ± 0.79

4.04 ± 0.78*++

-8.4++

Placebo

4.45 ± 0.90

4.75 ± 0.96

+7.4

 

 High-density lipoprotein cholesterol (HDL-C) (mmol/L) 

Policosanol

1.21 ± 0.39

1.29 ± 0.32*+

+6.6+

Placebo

1.21 ± 0.39

1.20 ± 0.33

-0.8

 

 Triglycerides (mmol/L) 

Policosanol

0.89 ± 0.45

1.01 ± 0.57*

+13.4

Placebo

0.93 ± 0.42

1.11 ± 0.60*

+19.4

X mean, SD standard deviation

 *p < 0.05 Comparison with baseline (McNemar test)

 +p < 0.05, ++p < 0.01, +++p<0.001 Comparison with placebo group (ANOVA)